252 related articles for article (PubMed ID: 32505908)
1. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
[TBL] [Abstract][Full Text] [Related]
2. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
3. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
4. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Fernández-Díaz E; Gracia-Gil J; García-García JG; Palao M; Romero-Sánchez CM; Segura T
Mult Scler Relat Disord; 2020 Oct; 45():102402. PubMed ID: 32711297
[TBL] [Abstract][Full Text] [Related]
6. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Foerch C; Friedauer L; Bauer B; Wolf T; Adam EH
Mult Scler Relat Disord; 2020 Jul; 42():102180. PubMed ID: 32408155
[TBL] [Abstract][Full Text] [Related]
7. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.
Devogelaere J; D'hooghe MB; Vanderhauwaert F; D'haeseleer M
Neurol Sci; 2020 Aug; 41(8):1981-1983. PubMed ID: 32564270
[TBL] [Abstract][Full Text] [Related]
8. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in MS: Initial observations from the Pacific Northwest.
Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
[No Abstract] [Full Text] [Related]
10. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
11. Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.
Mallucci G; Zito A; Fabbro BD; Bergamaschi R
Mult Scler Relat Disord; 2020 Oct; 45():102414. PubMed ID: 32711296
[No Abstract] [Full Text] [Related]
12. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
Gomez-Mayordomo V; Montero-Escribano P; Matías-Guiu JA; González-García N; Porta-Etessam J; Matías-Guiu J
J Med Virol; 2021 Jan; 93(1):546-549. PubMed ID: 32644205
[TBL] [Abstract][Full Text] [Related]
13. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
14. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Wurm H; Attfield K; Iversen AK; Gold R; Fugger L; Haghikia A
Mult Scler; 2020 Sep; 26(10):1261-1264. PubMed ID: 32762494
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
Racke MK; Newsome SD
J Neuroimmunol; 2020 Aug; 345():577283. PubMed ID: 32518058
[No Abstract] [Full Text] [Related]
16. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Barzegar M; Mirmosayyeb O; Nehzat N; Sarrafi R; Khorvash F; Maghzi AH; Shaygannejad V
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32371550
[No Abstract] [Full Text] [Related]
17. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
18. Concurrent COVID-19 and Pneumocystis jirovecii pneumonia in a severely immunocompromised 25-year-old patient.
Bhat P; Noval M; Doub JB; Heil E
Int J Infect Dis; 2020 Oct; 99():119-121. PubMed ID: 32768700
[No Abstract] [Full Text] [Related]
19. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
20. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
